Abbott India Limited vs Pfizer Limited
An objective side-by-side of ABBOTINDIA and PFIZER, both in Pharmaceuticals - Multinational: valuation, profitability, growth, balance sheet, ownership and share-price performance. Where one number is clearly better on its own terms (lower P/E, higher ROE), it is shaded. That is a description, not a recommendation.
Prices as of 2026-11-05 close
Latest results: ABBOTINDIA Jun 2026 · PFIZER Sep 2026
At a glance
- Abbott India Limited is the larger company by market value, about 3.2 times the size of Pfizer Limited.
- On trailing earnings, Pfizer Limited trades at the lower P/E (20.5 against 35.0).
- Abbott India Limited earns the higher return on equity (33.8% against 19.6%).
- Over three years Abbott India Limited has grown profits faster (18% a year against 8%).
- Over the past year the share prices returned -10.1% (ABBOTINDIA) and -27.5% (PFIZER).
| Metric | Abbott India ABBOTINDIA |
Pfizer PFIZER |
|---|---|---|
| Size and price | ||
| Market cap | ₹56,534 Cr | ₹17,644 Cr |
| Share price | ₹26,605.00 | ₹3,856.90 |
| Valuation | ||
| P/E | 35.00 | 20.53 |
| P/B | 11.84 | 4.02 |
| EV/EBITDA | 28.80 | 18.33 |
| PEG | 1.94 | 2.57 |
| Dividend yield | 2.0% | 2.0% |
| Profitability | ||
| ROE | 33.8% | 19.6% |
| ROCE | 45.0% | 24.0% |
| Operating margin | 28.1% | 36.7% |
| Sales (TTM) | ₹7,005 Cr | ₹2,654 Cr |
| Net profit (TTM) | ₹1,615 Cr | ₹859 Cr |
| Growth | ||
| Latest quarter sales YoY | +4.4% | +13.2% |
| Latest quarter profit YoY | +17.2% | +65.7% |
| Sales CAGR 3Y | +9.0% | +1.0% |
| Profit CAGR 3Y | +18.0% | +8.0% |
| Sales CAGR 5Y | +10.0% | +2.0% |
| Profit CAGR 5Y | +18.0% | +9.0% |
| Financial strength | ||
| Debt/Equity | 0.04 | 0.04 |
| Interest cover | 72.60 | 94.11 |
| Ownership | ||
| Promoter holding | 75.0% | 63.9% |
| Promoter change (4 qtrs) | — | +0.00 pp |
| Price performance | ||
| Return 1M | +1.88% | +0.12% |
| Return 3M | -4.25% | -21.42% |
| Return 1Y | -10.12% | -27.47% |
| Return YTD | -8.34% | -22.67% |
| Technical condition | ||
| Technical score | 57 | 55 |
| RS rating (1-99) | 57.00 | 20.00 |
| % vs 200-DMA | -0.08% | -15.56% |
| RSI (14) | 55.34 | 50.27 |
| % from 52-week high | -13.21% | -27.76% |
